-
The Clinton Foundation announced the successful conclusion of negotiations with several pharmaceutical companies to provide lower cost HIV testing and treatment to poorer countries. Four companies3 from India and 1 from South Africa have agreed to provide nevirapine and abacavir (at $USD 240 and $447 per patient per year, respectively), provided that certain conditions are met on an ongoing basis.
-
Do Antidepressants Increase Risk of Suicide?; Can Viagra Improve Heart Function?; A Dramatic Increase of Clostridium difficile; FDA Actions
-
-
Black women in the United States had the highest new diagnosis rate of HIV/AIDS of any ethnic/gender group between 2001 and 2004, according to the latest data from the Centers for Disease Control and Prevention (CDC) in Atlanta, GA.
-
The Food and Drug Administration (FDA), on Dec. 27, 2005, granted tentative approval, through an expedited procedure, to generic Nevirapine Oral Suspension, 50 mg/5 mL, manufactured by Aurobindo Pharma LTD., of Hyderabad, India.
-
-
Recent research has highlighted the cardiovascular problems that some HIV patients have had while being treated with protease inhibitors (PIs), but its been difficult for physicians to determine exactly which drugs are causing the most trouble.
-
Investigators have developed a clinical reminder that provides clinicians with a simple guide to when its important to offer HIV testing to patients.
-
Behavioral compliance interventions typically are time-consuming and costly, but it might work more efficiently if clinicians quickly could identify the patients most in need of such assistance.
-
Many people infected with HIV look to natural health products to supplement their conventional medical care, and clinicians, understandably, are concerned about drug interactions.
